AzTrials
AzTrials

Hepatitis C Virus (HCV)Phase 3EXPEDITION-8NCT03089944

A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

A Phase 3 study testing Glecaprevir/Pibrentasvir in people with Hepatitis C Virus (HCV), run by AbbVie at 113 sites in 19 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate the efficacy of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hepatitis C Virus (HCV)
What is being tested?
Glecaprevir/Pibrentasvir
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
343 participants
Where
113 sitesin 19 countries
Study dates
28 Apr 2017to 8 Nov 2019
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Screening laboratory result indicating Hepatitis C Virus (HCV) Genotype (GT) 1-6 infection.
  • Positive plasma HCV antibody and HCV RNA viral load greater than or equal to 1000 IU/mL at Screening.
  • Treatment-naive to any approved or investigational anti-HCV medication.
  • Participant must be documented as cirrhotic, with a Child-Pugh score of less than or equal to 6.

Who cannot join

  • Female participant who is pregnant, breastfeeding or is considering becoming pregnant during the study, or for approximately 30 days after the last dose of study drug.
  • Any current or historical clinical evidence of decompensated cirrhosis.
  • Positive test result at Screening for hepatitis B surface antigen (HBsAg), HBV deoxyribonucleic acid > lower limit of quantification (LLOQ) in subjects with isolated positive antibody to hepatitis B core antigen (anti-HBc) (i.e., negative HBsAg and anti-hepatitis B),or anti human immunodeficiency virus antibody (HIV Ab).
  • HCV genotype performed by the central laboratory during screening indicating co-infection with more than one HCV genotype.
  • History of suspected or confirmed hepatocellular carcinoma.

Trial locations and contacts

113 sites in 19 countries.

113 sites in 19 countries

United States40 sites

  • Lehigh Valley Health Network /ID# 162603

    Allentown, Pennsylvania, 18103

  • Piedmont Hospital /ID# 162646

    Atlanta, Georgia, 30309

  • Felizarta /ID# 162295

    Bakersfield, California, 93301

  • Mercy Medical Center /ID# 162291

    Baltimore, Maryland, 21202

  • Northwestern University Feinberg School of Medicine /ID# 162208

    Chicago, Illinois, 60611-2927

  • University Hospitals Cleveland /ID# 162243

    Cleveland, Ohio, 44106

  • Cleveland Clinic /ID# 162570

    Cleveland, Ohio, 44111

  • Texas Digestive Disease Consul /ID# 162648

    Dallas, Texas, 75246-1613

  • Unity Point Health /ID# 162247

    Des Moines, Iowa, 50309

  • Duke University Medical Center /ID# 162299

    Durham, North Carolina, 27710-3000

  • Cumberland Research Assoc /ID# 162212

    Fayetteville, North Carolina, 28304

  • University of Texas Health /ID# 162288

    Houston, Texas, 77030-1501

  • The University of Iowa Hospita /ID# 162214

    Iowa City, Iowa, 52242

  • Southern Therapy and Advanced Research (STAR) LLC /ID# 162241

    Jackson, Mississippi, 39216

  • Liver Wellness Center /ID# 162244

    Little Rock, Arkansas, 72204

  • VA Long Beach Healthcare System /ID# 162298

    Long Beach, California, 90822

  • Usc /Id# 162248

    Los Angeles, California, 90033

  • University of Louisville /ID# 162242

    Louisville, Kentucky, 40202

  • Univ of Wisconsin Hosp/Clinics /ID# 162645

    Madison, Wisconsin, 53792-0001

  • University of Miami /ID# 162210

    Miami, Florida, 33136

  • Vanderbilt Univ Med Ctr /ID# 162211

    Nashville, Tennessee, 37232-0011

  • Weill Cornell Medical College /ID# 161051

    New York, New York, 10021

  • Icahn School of Med Mt. Sinai /ID# 162294

    New York, New York, 10029

  • Rnjms /Id# 162213

    Newark, New Jersey, 07103

  • CHI Health Alegent Creighton /ID# 162286

    Omaha, Nebraska, 68124

  • Univ Nebraska Med Ctr /ID# 162285

    Omaha, Nebraska, 68198

  • St. Josephs Hosp and Med Ctr /ID# 162762

    Phoenix, Arizona, 85013

  • Mayo Clinic Arizona /ID# 162314

    Phoenix, Arizona, 85054

  • Center for Liver Diseases, Oakland /ID# 162568

    Pittsburgh, Pennsylvania, 15213

  • Virginia Commonwealth Univ /ID# 162215

    Richmond, Virginia, 23219

  • Mayo Clinic - Rochester /ID# 162251

    Rochester, Minnesota, 55905-0001

  • Kaiser Permanente - San Diego (Palm Ave) /ID# 162289

    San Diego, California, 92154

  • Louisiana Research Ctr. LLC /ID# 162567

    Shreveport, Louisiana, 71105-6800

  • Stanford University School of Med /ID# 162209

    Stanford, California, 94305-2200

  • Carolinas Center for Liver Dis /ID# 162569

    Statesville, North Carolina, 28677-3471

  • Montefiore Medical Center /ID# 162312

    The Bronx, New York, 10461

  • James J. Peters VA Medical Center /ID# 162644

    The Bronx, New York, 10468

  • Osuchs /Id# 162284

    Tulsa, Oklahoma, 74127

  • Cedars-Sinai Medical Center - West Hollywood /ID# 162313

    West Hollywood, California, 90048

  • Triple O Research Institute /ID# 162300

    West Palm Beach, Florida, 33407-3100

Other trials in United States

France6 sites

  • CHU Amiens Picardie /ID# 163071

    Amiens, Somme, 80054

  • CHU Estaing /ID# 163058

    Clermont-Ferrand, 63100

  • Hospital Henri Mondor /ID# 163061

    Créteil, 94010

  • Hopital de la Croix Rousse /ID# 163073

    Lyon, 69004

  • CHR Orleans - Hopital de la Source /ID# 163072

    Orléans, Centre-Val de Loire, 45067

  • Hôpital Purpan /ID# 163065

    Toulouse, Haute-Garonne, 31059

Other trials in France

Canada5 sites

  • University of Calgary /ID# 161185

    Calgary, Alberta, T2N 4Z6

  • Qe Ii Hsc /Id# 161178

    Halifax, Nova Scotia, B3H 1V7

  • The Ottawa Hospital Research /ID# 161179

    Ottawa, Ontario, K1H 8L6

  • Toronto General Hospital /ID# 161182

    Toronto, Ontario, M5G 2C4

  • Percuro Clinical Research, Ltd /ID# 161184

    Victoria, British Columbia, V8V 3M9

Other trials in Canada

Italy5 sites

  • A.O.U. Policlinico S.Orsola-Malpighi /ID# 162335

    Bologna, Emilia-Romagna, 40138

  • ASST Grande Ospedale Metropolitano Niguarda /ID# 162340

    Milan, Lombardy, 20162

  • Polo Universitario Luigi Sacco /ID# 162339

    Milan, 20157

  • Universita della Campania Luigi Vanvitelli /ID# 162337

    Naples, Campania, 80131

  • Istituto Clinico Humanitas /ID# 162336

    Rozzano, Milano, 20089

Other trials in Italy

Romania5 sites

  • Institutul Nat. de Boli Infectioase /ID# 163488

    Bucharest, 010825

  • Institutul National de Boli Infectioase Prof. Dr. Matei Bals /ID# 163484

    Sector 2, Bucharest, 021105

  • Institutul National de Boli Infectioase Prof. Dr. Matei Bals /ID# 164449

    Sector 2, Bucharest, 021105

  • Institutul Clinic Fundeni /ID# 163479

    Sector 2, Bucharest, 022328

  • Institutul Clinic Fundeni /ID# 163500

    Sector 2, Bucharest, 022328

Other trials in Romania

Russia5 sites

  • CBSI Central scientific and research institute of epidemiology /ID# 161996

    Moscow, 105275

  • Central Clinical Hospital of R /ID# 163434

    Moscow, 117593

  • LLC Medical Company Hepatolog /ID# 161998

    Samara, Samara Oblast, 443063

  • Stavropol State Medical Univ /ID# 161999

    Stavropol, 355017

  • RSAHI Consulting and Diagnostic Centre /ID# 161995

    Tyumen, 625026

Other trials in Russia

Spain5 sites

  • Hospital Parc de Salut del Mar /ID# 162198

    Barcelona, 08003

  • Hospital Univ Vall d'Hebron /ID# 162199

    Barcelona, 08035

  • Hospital Universitario Reina S /ID# 162200

    Córdoba, 14004

  • Hospital Donostia /ID# 162197

    Donostia / San Sebastian, 20080

  • Hospital Univ Central Asturias /ID# 162195

    Oviedo, 33011

Other trials in Spain

United Kingdom5 sites

  • Basildon University Hospital /ID# 162616

    Basildon, Essex, SS16 5NL

  • North Manchester General /ID# 163945

    Crumpsall, M8 5RB

  • Western General Hospital /ID# 162612

    Edinburgh, EH4 2XU

  • The Royal Free Hospital /ID# 162614

    London, London, City of, NW3 2QG

  • Queens Medical Centre /ID# 162615

    Nottinghamshire, NG7 2UH

Other trials in United Kingdom

Bulgaria4 sites

  • Tokuda Hospital Sofia /ID# 163422

    Sofia, 1407

  • DCC Fokus-5 - LZIP /ID# 163338

    Sofia, 1463

  • Univ Hosp for Active Treat /ID# 163330

    Sofia, 1527

  • UMHAT Sv. Ivan Rilski /ID# 163332

    Sofia, 1612

Other trials in Bulgaria

Greece4 sites

  • General Hospital of Athens Laiko /ID# 162786

    Athens, Attica, 115 27

  • General and Oncology Hospital /ID# 162784

    Kifissia, 14564

  • Reg Gen Univ Hosp Larissa /ID# 162783

    Larissa, 41110

  • Bioclinic Thessaloniki /ID# 162785

    Thessaloniki, 54622

Other trials in Greece

Israel4 sites

  • Rambam Health Care Campus /ID# 162023

    Haifa, 3109601

  • The Lady Davis Carmel MC /ID# 162017

    Haifa, 3436212

  • Sheba Medical Center /ID# 162028

    Ramat Gan, 5262100

  • Tel Aviv Sourasky Medical Ctr /ID# 162185

    Tel Aviv, Tel Aviv, 6423906

Other trials in Israel

Poland4 sites

  • Uniwersytecki Szpital Kliniczn /ID# 162757

    Bialystok, 15-276

  • HepID - Diagnostyka I Terapia /ID# 162761

    Lublin, Lublin Voivodeship, 20-884

  • ID Clinic /ID# 162759

    Mysłowice, 41-406

  • Centrum Badan Klinicznych, Przychodnia Badan Klinicznych /ID# 162760

    Wroclaw, Lower Silesian Voivodeship, 50-349

Other trials in Poland

Portugal4 sites

  • Centro Hosp de Lisboa Central /ID# 163770

    Lisbon, Lisbon District, 1169-050

  • Centro Hospitalar Lisboa Norte, EPE /ID# 163785

    Lisbon, 1649-035

  • Centro Hospitalar do Porto EPE /ID# 163765

    Porto, 4099-001

  • Centro Hospitalar de Sao Joao /ID# 163766

    Porto, 4200-319

Other trials in Portugal

Czechia3 sites

  • Research Site s.r.o /ID# 163020

    Pilsen, 301 00

  • KlinMed s.r.o. /ID# 162893

    Prague, 120 00

  • Institut Klinicke a Experimeth /ID# 162900

    Prague, 140 21

Other trials in Czechia

Ireland3 sites

  • St. James's Hospital /ID# 162619

    Dublin, Dublin, D08 E9P6

  • Beaumont Hospital /ID# 162618

    Dublin, D09 XR63

  • St Vincent's Hospital /ID# 162617

    Dublin

Other trials in Ireland

Puerto Rico3 sites

  • GHGCPR Research Institute /ID# 162608

    Ponce, 00716

  • Instituto de Investigacion Cientifica del Sur /ID# 162566

    Ponce, 00730

  • Klinical Investigations Group /ID# 162565

    San Juan, 00909

Other trials in Puerto Rico

Taiwan3 sites

  • Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 162949

    Kaohsiung City, 80708

  • China Medical University Hosp /ID# 162950

    Taichung, Taichung, 40447

  • Taipei Veterans General Hosp /ID# 162776

    Taipei, 11217

Other trials in Taiwan

Vietnam3 sites

  • National Hospital of Tropical Diseases /ID# 167974

    Hanoi, 100000

  • Hoa Hao Medic Co. Ltd. /ID# 168178

    Ho Chi Minh City, 700000

  • Tropical Diseases Hospital /ID# 168211

    Ho Chi Minh City, 700000

Other trials in Vietnam

Hungary2 sites

  • Budai Hepatologiai Centrum /ID# 166511

    Budapest, 1111

  • Szent Janos Korhaz /ID# 166542

    Budapest, 1125

Other trials in Hungary

About this study

Official title: A Single Arm, Open-label Study to Evaluate the Efficacy and Safety of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment Naïve Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis

A Phase 3b, single arm, open-label, multicenter study in treatment naïve adults with chronic HCV infection and compensated cirrhosis to assess the safety of 8 weeks of treatment with glecaprevir/pibrentasvir and to demonstrate the efficacy of the sustained virologic response 12 weeks post dosing (SVR12) rates of 8 weeks of treatment with glecaprevir/pibrentasvir compared to the historical SVR12 rates of 12 weeks of treatment with glecaprevir/pibrentasvir.

Being tested
Glecaprevir/Pibrentasvir
Keywords
Hepatitis C Virus (HCV), Glecaprevir, Pibrentasvir, Treatment Naïve, Cirrhosis, Compensated Cirrhosis, Genotype (GT) 1-6, Pangenotypic, Chronic Hepatitis C Virus (HCV)
Medical subject headings
Hepatitis C, Fibrosis, Hepatitis C, Chronic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Glecaprevir/PibrentasvirDrug

    Also called ABT-493, ABT-530

    Tablet

Study groups in NCT03089944
Study groupRoleWhat they receive
Glecaprevir (GLE)/Pibrentasvir (PIB) for 8 weeksExperimentalGlecaprevir (GLE)/Pibrentasvir (PIB) 300 mg/120 mg once daily (QD) for 8 weeks.
Receives: Drug: Glecaprevir/Pibrentasvir

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants in the Per Protocol (PP) Population

    SVR12 was defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) level less than the lower limit of quantification (<LLOQ; less than 15 IU/mL) 12 weeks after the last dose of study drug. Efficacy of the 8-week treatment duration compared to the historical 12-week treatment duration was demonstrated if the lower bound of the 2-sided 95% confidence interval (CI) for the percentage of participants with HCV GT1, GT2, GT4, GT5, or GT6 infection in the 8 week treatment duration achieving SVR12 was greater than 94% in the PP population. Efficacy analyses were performed following a fixed-sequence testing procedure to control the type I error rate. The percentage of participants achieving SVR12 was summarized with a 2-sided 95% CI, calculated using the normal approximation to the binomial distribution. If the number of participants who failed to achieve SVR12 rate was less than 5, the Wilson's score method was used to calculate the CI.

    Measured: 12 weeks after last dose of study drug

  2. Percentage of Participants With SVR12 in HCV GT 1,2,4,5 and 6-infected Participants in the Intent-To-Treat (ITT) Population

    SVR12 was defined as HCV RNA level less than the LLOQ (less than 15 IU/mL) 12 weeks after the last dose of study drug. Efficacy of the 8-week treatment duration compared to the historical 12-week treatment duration was demonstrated if the lower bound of the 2-sided 95% CI for the percentage of participants with HCV GT1, GT2, GT4, GT5, or GT6 infection in the 8 week treatment duration achieving SVR12 was greater than 93% in the ITT population. Primary efficacy analyses were performed following a fixed-sequence testing procedure to control the type I error rate. The percentage of participants achieving SVR12 was summarized with a 2-sided 95% CI, calculated using the normal approximation to the binomial distribution. If the number of participants who failed to achieve SVR12 rate was less than 5, the Wilson's score method was used to calculate the CI.

    Measured: 12 weeks after last dose of study drug

Secondary outcomes (6)

  1. Percentage of Participants With SVR12 in HCV GT1-6-infected Participants in the PP Population

    SVR12 was defined as HCV RNA level less than the LLOQ (less than 15 IU/mL) 12 weeks after the last dose of study drug. Efficacy of the 8-week treatment duration compared to the historical 12-week treatment duration was demonstrated if the lower bound of the 2-sided 95% CI for the percentage of participants with HCV GT1, GT2, GT3, GT4, GT5, or GT6 infection in the 8 week treatment duration achieving SVR12 was greater than 94% in the PP population. These efficacy analyses were performed only if success was demonstrated for both primary efficacy analyses, following a fixed-sequence testing procedure.

    Measured: 12 weeks after last dose of study drug

  2. Percentage of Participants With SVR12 in HCV GT1-6-infected Participants in the ITT Population

    SVR12 was defined as HCV RNA level less than the LLOQ (less than 15 IU/mL) 12 weeks after the last dose of study drug. Efficacy of the 8-week treatment duration compared to the historical 12-week treatment duration was demonstrated if the lower bound of the 2-sided 95% CI for the percentage of participants with HCV GT1, GT2, GT3, GT4, GT5, or GT6 infection in the 8 week treatment duration achieving SVR12 was greater than 93% in the ITT population. These efficacy analyses were performed only if success was demonstrated for both primary efficacy analyses, following a fixed-sequence testing procedure.

    Measured: 12 weeks after the last dose of study drug

  3. Percentage of Participants With On-treatment Virologic Failure in the ITT Population

    On-treatment virologic failure was defined as confirmed HCV RNA ≥ 100 IU/mL after HCV RNA < LLOQ during treatment; confirmed increase of > 1 log(subscript)10(subscript) IU/mL above the lowest value post-baseline in HCV RNA during treatment; or HCV RNA ≥ LLOQ at end of treatment with at least 6 weeks of treatment.

    Measured: 8 weeks on treatment

  4. Percentage of Participants With Post-treatment Relapse

    Post-treatment relapse was defined as confirmed HCV RNA ≥ LLOQ between the end of treatment and 12 weeks after the last dose of study drug among participants who completed treatment as planned (defined as study drug duration ≥ 52 days for participants assigned to 8 weeks of treatment) and with HCV RNA levels < LLOQ at the end of treatment excluding participants who had been reinfected.

    Measured: Up to 12 weeks after the last dose of study drug

  5. Percentage of HCV GT3-infected Participants Who Achieved SVR12 in the PP Population

    SVR12 was defined as HCV RNA level less than the LLOQ (less than 15 IU/mL) 12 weeks after the last dose of study drug.

    Measured: 12 weeks after the last dose of study drug

  6. Percentage of HCV GT3-infected Participants Who Achieved SVR12 in the ITT Population

    SVR12 was defined as HCV RNA level less than the LLOQ (less than 15 IU/mL) 12 weeks after the last dose of study drug.

    Measured: 12 weeks after the last dose of study drug

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Mar 2017
  2. Study start28 Apr 2017
  3. Primary completion31 Jul 2019
  4. Study completion8 Nov 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
343 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03089944
Sponsor's protocol ID
M16-135
Other IDs
2016-004967-38, 2016
Acronym
EXPEDITION-8
Status last verified
Jun 2020
First submitted
22 Mar 2017
Last updated
13 Jul 2020
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
Expanded access
Available

Publications

  • Brown RS Jr, Buti M, Rodrigues L, Chulanov V, Chuang WL, Aguilar H, Horvath G, Zuckerman E, Carrion BR, Rodriguez-Perez F, Urbanek P, Abergel A, Cohen E, Lovell SS, Schnell G, Lin CW, Zha J, Wang S, Trinh R, Mensa FJ, Burroughs M, Felizarta F. Glecaprevir/pibrentasvir for 8 weeks in treatment-naive patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol. 2020 Mar;72(3):441-449. doi: 10.1016/j.jhep.2019.10.020. Epub 2019 Nov 2.

    PubMed 31682879

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Glecaprevir/Pibrentasvir in people with Hepatitis C Virus (HCV), run by AbbVie at 113 sites in 19 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Jul 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 113 sites in United States, France, Canada, Italy, Romania and 14 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 13 Jul 2020). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants With Sustained Virologic Response 12 Weeks Post-treatment (SVR12) in Hepatitis C Virus (HCV) Genotype (GT) 1,2,4,5 and 6-infected Participants in the Per Protocol (PP) Population (time frame: 12 weeks after last dose of study drug). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03089944, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Jul 2020.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in